The phase II RAGNAR trial demonstrated the benefit of erdafitinib in numerous non–urothelial carcinoma solid tumors harboring any activating FGFR1-4 alterations.30 Besides erdafitinib, other FGFR inhibitors, including futibatinib, infigratinib, and pemigatinib, have been approved by the FDA for the treatment of cholangiocarcinoma31-33; pemigatinib has been approved for myeloid/lymphoid neoplasm.34 Options for FGFR-targeted therapy are numerous yet underexplored in urinary tract carcinomas. Here, FGFR1 is linked to urothelial carcinoma.